Measurement science and regulatory strategy expert to lead global patient-focused endpoint initiatives.Continue reading
Author Archive: Roxan Olivas
C-Path Concludes 2026 Global Impact Conference with a Shared Agenda for Rebuilding Evidence Generation
Regulators, industry leaders, scientists, and those with lived experience converged on how evidence is generated, interpreted, and acted upon across rare diseases, neurology, and pediatrics.Continue reading
C-Path’s Translational Therapeutics Accelerator Awards $1.7 Million Across Five BRIDGe Grants in Brain Health, Pediatrics and Rare Disease
Five research teams advance small molecule, protein-based and gene therapy candidates for conditions where existing options fall short for those most affectedContinue reading
C-Path Mourns the Passing of Board Member Peter Barton Hutt
TUCSON, Ariz., September 3, 2026 — Critical Path Institute® (C-Path) is deeply saddened to announce the passing of Peter Barton Hutt, a longtime member of C-Path’s Board of Directors, on September 2, 2026.Continue reading
Critical Path for Parkinson’s Announces Milestone Publication Highlighting FDA Support for Novel Biomarker to Advance Precision Medicine Strategies
Journal of Parkinson’s Disease recognizes a decade of collaborative progress culminating in regulatory endorsement for biomarkers to enable early interventionContinue reading
C-Path Achieves Internationally Recognized Certification for Information Security Management
TUCSON, Ariz., August 20, 2026 – Critical Path Institute® (C-Path) today announced it has achieved certification to ISO/IEC 27001:2022, the internationally recognized standard for information security management systems (ISMS), awarded by the Johanson Group, LLP, following an independent audit.Continue reading
Crown Bioscience Joins C-Path’s New Approach Methodologies Developer Coalition
Global contract research organization specializing in translational oncology brings its preclinical model and biomarker capabilities to the coalition’s work advancing the adoption and qualification of new approach methodologies.Continue reading
Karen Bernstein, One of Biotech’s Most Influential Voices, Elected C-Path Board Chair
BioCentury co-founder succeeds Wain Fishburn, effective July 1Continue reading
C-Path Awards $250,000 Grant to Advance New Treatment for Sepsis-Associated Neurocognitive Dysfunction
TUCSON, Ariz., July 9, 2026 — Critical Path Institute® (C-Path) has awarded a $250,000 research grant to Teresa Sanchez, Ph.D., of Weill Cornell Medicine, to support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction.Continue reading
C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies.Continue reading